1. Home
  2. AACT vs SLP Comparison

AACT vs SLP Comparison

Compare AACT & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AACT
  • SLP
  • Stock Information
  • Founded
  • AACT 2021
  • SLP 1996
  • Country
  • AACT United States
  • SLP United States
  • Employees
  • AACT N/A
  • SLP N/A
  • Industry
  • AACT
  • SLP EDP Services
  • Sector
  • AACT
  • SLP Technology
  • Exchange
  • AACT Nasdaq
  • SLP Nasdaq
  • Market Cap
  • AACT 697.5M
  • SLP 675.9M
  • IPO Year
  • AACT 2023
  • SLP 1997
  • Fundamental
  • Price
  • AACT $11.37
  • SLP $16.96
  • Analyst Decision
  • AACT
  • SLP Buy
  • Analyst Count
  • AACT 0
  • SLP 7
  • Target Price
  • AACT N/A
  • SLP $35.40
  • AVG Volume (30 Days)
  • AACT 280.5K
  • SLP 612.3K
  • Earning Date
  • AACT 01-01-0001
  • SLP 07-14-2025
  • Dividend Yield
  • AACT N/A
  • SLP 0.35%
  • EPS Growth
  • AACT N/A
  • SLP N/A
  • EPS
  • AACT 0.36
  • SLP 0.36
  • Revenue
  • AACT N/A
  • SLP $78,564,000.00
  • Revenue This Year
  • AACT N/A
  • SLP $27.66
  • Revenue Next Year
  • AACT N/A
  • SLP $6.75
  • P/E Ratio
  • AACT $31.44
  • SLP $47.10
  • Revenue Growth
  • AACT N/A
  • SLP 21.49
  • 52 Week Low
  • AACT $10.68
  • SLP $16.72
  • 52 Week High
  • AACT $11.62
  • SLP $44.33
  • Technical
  • Relative Strength Index (RSI)
  • AACT 60.49
  • SLP 28.76
  • Support Level
  • AACT $11.31
  • SLP $16.75
  • Resistance Level
  • AACT $11.36
  • SLP $18.09
  • Average True Range (ATR)
  • AACT 0.04
  • SLP 0.81
  • MACD
  • AACT 0.00
  • SLP 0.40
  • Stochastic Oscillator
  • AACT 94.44
  • SLP 10.76

About AACT Ares Acquisition Corporation II

Ares Acquisition Corp II is a blank check company.

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Share on Social Networks: